Aurobindo Pharma signs agreement to produce key HIV drugs

MUMBAI: Aurobindo Pharma has signed an agreement with public health organisation, Medicines Patent Pool that will allow it to produce key medicines for treatment of children living with HIV. Through a patent licence with the MPP, Aurobindo can now supply medicines containing abacavir in 118 countries where over 98% of children living with HIV reside. Abacavir is recommended by the World Health Organization for the treatment of paediatric HIV.

There are currently 3.4 million children living with HIV worldwide. But only 562,000 of them have access to medicines, according to the World Health Organization (WHO).

"Treating children living with HIV can be challenging, as medicines suited to their specific needs are often unavailable. With this licence, Aurobindo looks forward to increasing the supply of quality, child-friendly HIV treatment in developing countries," said PV Ramaprasad Reddy, chairman Aurobindo.

The Medicines Patent Pool made the abacavir licence available for generic companies following an agreement it signed with ViiV Healthcare (a joint venture of GlaxoSmithKline, Pfizer, and Shionogi) in February 2013.

"Quality medicines at affordable prices are critical for combating the HIV epidemic, and generic manufacturers like Aurobindo are an essential part of ensuring such medicines are available," said Greg Perry, executive director Medicines Patent Pool. "The agreement with ViiV is an important initial step towards making more child-friendly HIV medicines available where they are most needed."

Anda sedang membaca artikel tentang

Aurobindo Pharma signs agreement to produce key HIV drugs

Dengan url

https://cegahkeropostulang.blogspot.com/2013/06/aurobindo-pharma-signs-agreement-to.html

Anda boleh menyebar luaskannya atau mengcopy paste-nya

Aurobindo Pharma signs agreement to produce key HIV drugs

namun jangan lupa untuk meletakkan link

Aurobindo Pharma signs agreement to produce key HIV drugs

sebagai sumbernya